SEC Company Response from INNOCAN PHARMA (INNPF) — Jan 27, 2026
INNOCAN PHARMA Corp
Date: Jan. 27, 2026 · CIK: 0001889791 · Accession: 0001493152-26-003784
AI Filing Summary & Sentiment
File numbers found in text: 333-288899
Show Raw Text
CORRESP 1 filename1.htm January 27, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Innocan Pharma Corporation (CIK 0001889791) Registration Statement No. 333-288899 on Form F-1 (the "Registration Statement") Ladies and Gentlemen: In accordance with Rule 461 promulgated under the Securities Act of 1933, as amended (the "Securities Act"), ThinkEquity LLC, as representative of the underwriters, hereby requests acceleration of the effective date of the above-referenced Registration Statement so that it will become effective at 5:00 p.m. Eastern Time on January 29, 2026, or as soon thereafter as practicable. Pursuant to Rule 460 under the Securities Act, please be advised that there will be distributed to each underwriter, who is reasonably anticipated to be invited to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus. The undersigned confirms that it has complied with and will continue to comply with, and it has been informed or will be informed by participating dealers that they have complied with or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue. Very truly yours, ThinkEquity LLC By: /s/ Eric Lord Name: Eric Lord Title: Head of Investment Banking